Bile acids and metabolic syndrome

Hiroki Taoka, Mitsuhiro Watanabe

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bile acids (BAs) are not only facilitators of dietary lipid absorption but also important signaling molecules that participate in various metabolic pathways. Some major signaling pathways involving the nuclear BAs receptor farnesoid X receptor (FXR) and the G protein-coupled BAs receptor TGR5/M-BAR have been identified to be the targets of BAs. BAs affect diverse metabolic pathways including glucose metabolism, lipid metabolism, and energy expenditure via these major pathways. Therefore, BA signaling mechanisms are attractive therapeutic targets of the metabolic syndrome. Actually, bile acid-binding resin (BABR) originally used to treat hypercholesterolemia also stimulates incretin secretion and improves glucose metabolism. In addition to BABR, the clinical applications of FXR and TGR5/M-BAR agonists are ongoing for the treatment of metabolic syndrome. The effects of bariatric surgery on glycemic control are also associated with BA metabolism. In this chapter, we summarize current knowledge of the metabolic regulation mechanisms of BAs and propose BA signaling pathways as a therapeutic target of the metabolic syndrome.

Original languageEnglish
Title of host publicationBile Acids in Gastroenterology
Subtitle of host publicationBasic and Clinical
PublisherSpringer Japan
Pages193-209
Number of pages17
ISBN (Electronic)9784431560623
ISBN (Print)9784431560609
DOIs
Publication statusPublished - 2017 Apr 3

Fingerprint

Bile Acids and Salts
Metabolic Networks and Pathways
Incretins
Glucose
Bariatric Surgery
G-Protein-Coupled Receptors
Hypercholesterolemia
Lipid Metabolism
Energy Metabolism
Therapeutics
Lipids

Keywords

  • Energy metabolism
  • Farnesoid X receptor
  • Glucose metabolism
  • Lipid metabolism
  • TGR5/M-BAR

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Taoka, H., & Watanabe, M. (2017). Bile acids and metabolic syndrome. In Bile Acids in Gastroenterology: Basic and Clinical (pp. 193-209). Springer Japan. https://doi.org/10.1007/978-4-431-56062-3_15

Bile acids and metabolic syndrome. / Taoka, Hiroki; Watanabe, Mitsuhiro.

Bile Acids in Gastroenterology: Basic and Clinical. Springer Japan, 2017. p. 193-209.

Research output: Chapter in Book/Report/Conference proceedingChapter

Taoka, H & Watanabe, M 2017, Bile acids and metabolic syndrome. in Bile Acids in Gastroenterology: Basic and Clinical. Springer Japan, pp. 193-209. https://doi.org/10.1007/978-4-431-56062-3_15
Taoka H, Watanabe M. Bile acids and metabolic syndrome. In Bile Acids in Gastroenterology: Basic and Clinical. Springer Japan. 2017. p. 193-209 https://doi.org/10.1007/978-4-431-56062-3_15
Taoka, Hiroki ; Watanabe, Mitsuhiro. / Bile acids and metabolic syndrome. Bile Acids in Gastroenterology: Basic and Clinical. Springer Japan, 2017. pp. 193-209
@inbook{bc5d278cb56a47ef8d303ca4aab9160e,
title = "Bile acids and metabolic syndrome",
abstract = "Bile acids (BAs) are not only facilitators of dietary lipid absorption but also important signaling molecules that participate in various metabolic pathways. Some major signaling pathways involving the nuclear BAs receptor farnesoid X receptor (FXR) and the G protein-coupled BAs receptor TGR5/M-BAR have been identified to be the targets of BAs. BAs affect diverse metabolic pathways including glucose metabolism, lipid metabolism, and energy expenditure via these major pathways. Therefore, BA signaling mechanisms are attractive therapeutic targets of the metabolic syndrome. Actually, bile acid-binding resin (BABR) originally used to treat hypercholesterolemia also stimulates incretin secretion and improves glucose metabolism. In addition to BABR, the clinical applications of FXR and TGR5/M-BAR agonists are ongoing for the treatment of metabolic syndrome. The effects of bariatric surgery on glycemic control are also associated with BA metabolism. In this chapter, we summarize current knowledge of the metabolic regulation mechanisms of BAs and propose BA signaling pathways as a therapeutic target of the metabolic syndrome.",
keywords = "Energy metabolism, Farnesoid X receptor, Glucose metabolism, Lipid metabolism, TGR5/M-BAR",
author = "Hiroki Taoka and Mitsuhiro Watanabe",
year = "2017",
month = "4",
day = "3",
doi = "10.1007/978-4-431-56062-3_15",
language = "English",
isbn = "9784431560609",
pages = "193--209",
booktitle = "Bile Acids in Gastroenterology",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Bile acids and metabolic syndrome

AU - Taoka, Hiroki

AU - Watanabe, Mitsuhiro

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Bile acids (BAs) are not only facilitators of dietary lipid absorption but also important signaling molecules that participate in various metabolic pathways. Some major signaling pathways involving the nuclear BAs receptor farnesoid X receptor (FXR) and the G protein-coupled BAs receptor TGR5/M-BAR have been identified to be the targets of BAs. BAs affect diverse metabolic pathways including glucose metabolism, lipid metabolism, and energy expenditure via these major pathways. Therefore, BA signaling mechanisms are attractive therapeutic targets of the metabolic syndrome. Actually, bile acid-binding resin (BABR) originally used to treat hypercholesterolemia also stimulates incretin secretion and improves glucose metabolism. In addition to BABR, the clinical applications of FXR and TGR5/M-BAR agonists are ongoing for the treatment of metabolic syndrome. The effects of bariatric surgery on glycemic control are also associated with BA metabolism. In this chapter, we summarize current knowledge of the metabolic regulation mechanisms of BAs and propose BA signaling pathways as a therapeutic target of the metabolic syndrome.

AB - Bile acids (BAs) are not only facilitators of dietary lipid absorption but also important signaling molecules that participate in various metabolic pathways. Some major signaling pathways involving the nuclear BAs receptor farnesoid X receptor (FXR) and the G protein-coupled BAs receptor TGR5/M-BAR have been identified to be the targets of BAs. BAs affect diverse metabolic pathways including glucose metabolism, lipid metabolism, and energy expenditure via these major pathways. Therefore, BA signaling mechanisms are attractive therapeutic targets of the metabolic syndrome. Actually, bile acid-binding resin (BABR) originally used to treat hypercholesterolemia also stimulates incretin secretion and improves glucose metabolism. In addition to BABR, the clinical applications of FXR and TGR5/M-BAR agonists are ongoing for the treatment of metabolic syndrome. The effects of bariatric surgery on glycemic control are also associated with BA metabolism. In this chapter, we summarize current knowledge of the metabolic regulation mechanisms of BAs and propose BA signaling pathways as a therapeutic target of the metabolic syndrome.

KW - Energy metabolism

KW - Farnesoid X receptor

KW - Glucose metabolism

KW - Lipid metabolism

KW - TGR5/M-BAR

UR - http://www.scopus.com/inward/record.url?scp=85033331122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033331122&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-56062-3_15

DO - 10.1007/978-4-431-56062-3_15

M3 - Chapter

AN - SCOPUS:85033331122

SN - 9784431560609

SP - 193

EP - 209

BT - Bile Acids in Gastroenterology

PB - Springer Japan

ER -